Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 3/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR4 | P46093 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291514 | 0.90 | BRD4 (0.49) | KDM4EMEN1KMT2AGPR4PDGFRB | |
| SCHEMBL30597772 | 0.86 | KDM4E (0.49) | PSMB1PSMB5PSMB2KDM4EPOLB | |
| SCHEMBL3043613 | 0.82 | PSMB1 (0.49) | PSMB1PSMB5PSMB2KDM4EPOLB | |
| SCHEMBL28917884 | 0.81 | PSMB1 (0.47) | PSMB1PSMB5PSMB2KDM4EPOLB | |
| SCHEMBL13291506 | 0.81 | NR1H2 (0.41) | KDM4EHRH3 | |
| SCHEMBL16424238 | 0.77 | HRH3 (0.52) | KDM4EPOLBKMT2AHRH3 | |
| SCHEMBL5315294 | 0.77 | AURKA (0.59) | PDGFRBPDGFRAFLT3HRH3 | |
| SCHEMBL12685165 | 0.77 | AKR1C3 (0.57) | KDM4EMEN1KMT2A | |
| SCHEMBL13646769 | 0.75 | AKR1C3 (0.43) | KDM4EMEN1KMT2A | |
| SCHEMBL8646222 | 0.75 | AKR1C3 (0.43) | KDM4EPOLBMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | PSMB1 3842/4885PSMB5 1200/4885PSMB2 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.